Skip to main navigation Skip to search Skip to main content

A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants

  • Reto Eggenschwiler
  • , Atanas Patronov
  • , Jan Hegermann
  • , Mariane Fráguas-Eggenschwiler
  • , Guangming Wu
  • , Leon Cortnumme
  • , Matthias Ochs
  • , Iris Antes
  • , Tobias Cantz
  • Hannover Medical School
  • Technical University of Munich
  • a joint venture between the Hanover Medical School and the Helmholtz Centre for Infection Research
  • Max Planck Institute for Molecular Biomedicine
  • Charité – Universitätsmedizin Berlin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Certain point-mutations in the human SERPINA1-gene can cause severe α1-antitrypsin-deficiency (A1AT-D). Affected individuals can suffer from loss-of-function lung-disease and from gain-of-function liver-disease phenotypes. However, age of onset and severity of clinical appearance is heterogeneous amongst carriers, suggesting involvement of additional genetic and environmental factors. The generation of authentic A1AT-D mouse-models has been hampered by the complexity of the mouse Serpina1-gene locus and a model with concurrent lung and liver-disease is still missing. Here, we investigate point-mutations in the mouse Serpina1a antitrypsin-orthologue, which are homolog-equivalent to ones known to cause severe A1AT-D in human. We combine in silico and in vitro methods and we find that analyzed mutations do introduce potential disease-causing properties into Serpina1a. Finally, we show that introduction of the King’s-mutation causes inactivation of neutrophil elastase inhibitory-function in both, mouse and human antitrypsin, while the mouse Z-mutant retains activity. This work paves the path to generation of better A1AT-D mouse-models.

Original languageEnglish
Article number7486
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants'. Together they form a unique fingerprint.

Cite this